Literature DB >> 29143021

Reversing the undesirable pH-profile of doxorubicin via activation of a di-substituted maleamic acid prodrug at tumor acidity.

Anqi Zhang1, Lan Yao, Ming An.   

Abstract

The acid-labile behavior of di-substituted maleamic acid (DMA) and its equilibrium with di-substituted maleimide (DMI) are exploited to build an ultra acid-sensitive, small molecule prodrug that can be activated by tumor extracellular pH (pHe) in the range of 6.5-6.9. Such a DMA prodrug reversed the unfavorable pH-profile of doxorubicin (Dox), which may improve its therapeutic window.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29143021     DOI： 10.1039/c7cc06843c

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  4 in total

1.  Radiometal-Based PET/MRI Contrast Agents for Sensing Tumor Extracellular pH.

Authors:  Alyssa C Pollard; Jorge de la Cerda; F William Schuler; Tyler R Pollard; Aikaterini Kotrotsou; Federica Pisaneschi; Mark D Pagel
Journal:  Biosensors (Basel)       Date:  2022-02-20

2.  Nanoporous Gold Monolith for High Loading of Unmodified Doxorubicin and Sustained Co-Release of Doxorubicin-Rapamycin.

Authors:  Jay K Bhattarai; Dharmendra Neupane; Bishal Nepal; Alexei V Demchenko; Keith J Stine
Journal:  Nanomaterials (Basel)       Date:  2021-01-15       Impact factor: 5.076

3.  Poly(ethylene glycol) based nanotubes for tuneable drug delivery to glioblastoma multiforme.

Authors:  Majed Alghamdi; Filippo Chierchini; Dimitri Eigel; Christian Taplan; Thomas Miles; Dagmar Pette; Petra B Welzel; Carsten Werner; Wenxin Wang; Catia Neto; Mark Gumbleton; Ben Newland
Journal:  Nanoscale Adv       Date:  2020-08-24

4.  Incorporation of nanogels within calcite single crystals for the storage, protection and controlled release of active compounds.

Authors:  Ouassef Nahi; Alexander N Kulak; Thomas Kress; Yi-Yeoun Kim; Ola G Grendal; Melinda J Duer; Olivier J Cayre; Fiona C Meldrum
Journal:  Chem Sci       Date:  2021-06-28       Impact factor: 9.825
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.